Respiratory syncytial virus
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study
Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus
GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership
GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval
GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination